SCHEMBL4331498

SCHEMBL4331498

COCCCNC(=S)N/N=C/c1ccc(-c2ccc(Cl)c(Cl)c2)o1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.61
KMT2A Q03164 5/20 0.61
HPGD P15428 4/20 0.61
MAPT P10636 9/20 0.61
ALDH1A1 P00352 8/20 0.61
NPSR1 Q6W5P4 3/20 0.61
HTT P42858 1/20 0.61
CRHBP P24387 1/20 0.59
CRHR2 Q13324 1/20 0.59
PHGDH O43175 3/20 0.58
GAA P10253 5/20 0.53
PKM P14618 1/20 0.53
KDM4E B2RXH2 6/20 0.53
MAPK1 P28482 2/20 0.52
LMNA P02545 3/20 0.52
POLB P06746 2/20 0.52
TDP1 Q9NUW8 1/20 0.52
L3MBTL1 Q9Y468 3/20 0.51
BLM P54132 1/20 0.51
ALOX12 P18054 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4331505 1.00 MEN1 (0.61) MEN1KMT2AHPGDMAPTALDH1A1
SCHEMBL4341230 0.86 KMT2A (0.68) MEN1KMT2AHPGDMAPTALDH1A1
SCHEMBL4341235 0.86 KMT2A (0.68) MEN1KMT2AHPGDMAPTALDH1A1
SCHEMBL13886982 0.84 PHGDH (0.77) MEN1KMT2AHPGDMAPTALDH1A1
SCHEMBL4455860 0.84 PHGDH (0.77) MEN1KMT2AHPGDMAPTALDH1A1
SCHEMBL4333754 0.84 KMT2A (0.63) MEN1KMT2AHPGDMAPTALDH1A1
SCHEMBL4333758 0.84 KMT2A (0.63) MEN1KMT2AHPGDMAPTALDH1A1
SCHEMBL4331625 0.83 MAPT (0.54) MEN1KMT2AHPGDMAPTALDH1A1
SCHEMBL4331633 0.83 MAPT (0.54) MEN1KMT2AHPGDMAPTALDH1A1
SCHEMBL13887126 0.81 KMT2A (0.74) MEN1KMT2AHPGDMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 MEN1 4874/4885KMT2A 3988/4885HPGD 1646/4885
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 MEN1 4872/4885KMT2A 3714/4885HPGD 1495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.